李广欣, 陈海英, 李景喆, 李锦毅, 张建忠, 朱露娟, 周洁. 原发性肝癌合并门静脉和下腔静脉癌栓的调强放疗疗效分析[J]. 中国肿瘤临床, 2016, 43(20): 898-901. DOI: 10.3969/j.issn.1000-8179.2016.20.637
引用本文: 李广欣, 陈海英, 李景喆, 李锦毅, 张建忠, 朱露娟, 周洁. 原发性肝癌合并门静脉和下腔静脉癌栓的调强放疗疗效分析[J]. 中国肿瘤临床, 2016, 43(20): 898-901. DOI: 10.3969/j.issn.1000-8179.2016.20.637
Guangxin LI, Haiying CHEN, Jingzhe LI, Jinyi LI, Jianzhong ZHANG, Lujuan ZHU, Jie ZHOU. Intensity modulated radiation therapy for primary liver cancer with portal vein/inferior vena cava tumor thrombosis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(20): 898-901. DOI: 10.3969/j.issn.1000-8179.2016.20.637
Citation: Guangxin LI, Haiying CHEN, Jingzhe LI, Jinyi LI, Jianzhong ZHANG, Lujuan ZHU, Jie ZHOU. Intensity modulated radiation therapy for primary liver cancer with portal vein/inferior vena cava tumor thrombosis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(20): 898-901. DOI: 10.3969/j.issn.1000-8179.2016.20.637

原发性肝癌合并门静脉和下腔静脉癌栓的调强放疗疗效分析

Intensity modulated radiation therapy for primary liver cancer with portal vein/inferior vena cava tumor thrombosis

  • 摘要: 目的:观察调强放疗治疗原发性肝癌(primary liver cancer ,PLC )合并门静脉(portal vein tumor thrombosis,PVTT)和(或)下腔静脉癌栓(inferior vena cava tumor thrombosis,IVTT)的效果及预后影响因素。方法:回顾分析2013年1 月至2015年5 月在武警北京总队第三医院放疗中心接受调强放疗(intensity modulated radiation therapy ,IMRT)的41例PLC 合并PVTT和(或)IVTT患者,放疗等效生物剂量(BED )48~94Gy。观察其近期、远期疗效,Log-rank 法进行单因素分析,Cox 模型进行多因素预后分析。结果:全组患者治疗不良反应轻微,≥ 2 级消化道反应、血液学毒性及放射性肝损伤发生率分别为29.3% 、26.8% 、14.6% 。放疗后CR、PR、SD、PD者分别为29.3% 、31.7% 、39.0% 和0,客观有效率61.0% 。全组患者1 年生存率34.1% ,中位生存期11个月。单因素分析中Child-Pugh 分级、治疗后AFP 水平、治疗前胆碱酯酶水平是影响预后的因素(P = 0.012、0.004、0.001)。 结论:IMRT 是治疗PLC 合并PVTT的一种安全有效的方法。

     

    Abstract: Objective:To evaluate the clinical outcomes of patients after intensity modulated radiation therapy (IMRT) for hepatocellu -lar carcinoma (HCC) with portal vein tumor thrombosis (PVTT) or inferior vena cava tumor thrombosis (IVTT). Methods:A registry data -base of41patients treated with IMRT for HCC with PVTT or IVTT in Radiotherapy Center of No.3 Hospital of Beijing Chinese People Armed Police Forces between January 2013and May 2015were analyzed retrospectively. The biological effective dose of radiation was ranged 48- 94Gy. Short-term effects and prospective efficacy were observed. Log-rank test, Cox regression were used for survival analysis and prognostic factor identification. Results: Grade 2 or higher level gastrointestinal reaction was observed in 12patients (29. 3% ). Hematological toxicity was observed in 11patients ( 26. 8% ), and radiation- induced liver disease was observed in6 patients (14. 6%). We found that29. 3% of patients achieved a complete response and 31. 7% of patients achieved a partial response. The stable and progressive disease rates were 39. 0% and 0. 0%, respectively. Median patient survival was11months, and the 1-year survival rate was 34. 1%. The significant independent variables associated with the overall survival included Child Pugh grade, AFP test, and CHE lev -el. Conclusion: IMRT is a safe and effective treatment for PVTT or IVTT in patients with HCC.

     

/

返回文章
返回